

Title Page

Title:

Diminished antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients

Authors: Ayman Al Jurdi,¹ Rodrigo B. Gassen,¹ Thiago J. Borges,¹ Isadora T. Lape,¹ Leela Morena,¹ Orhan Efe,¹ Zhabiz Solhjou,² Rania El Fekih,² Christa Deban,² Brigid Bohan,³ Vikram Pattanayak,⁴ Camille N. Kotton,⁵ Jamil R. Azzi,² Leonardo V. Riella.^{1*}

Affiliations:

¹Center for Transplantation Sciences, Massachusetts General Hospital; Boston, MA, USA

²Transplantation Research Center, Renal Division, Brigham and Women's Hospital; Boston, MA, USA

³Histocompatibility Laboratory, Massachusetts General Hospital; Boston, MA, USA

⁴Department of Pathology, Massachusetts General Hospital; Boston, MA, USA

⁵Transplant and Immunocompromised Host Infectious Diseases Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School; Boston, MA, USA

***Corresponding author:**

Leonardo V. Riella, MD PhD

149 13th St, Room 5102

Charlestown, MA 02129

Email: lriella@mgh.harvard.edu

Running title: SARS-CoV-2 variants immune response

Abstract word count: 244

Text word count: 2,038

Keywords: SARS-CoV-2, COVID-19, Kidney transplant, vaccine

Abstract:

Background: Available SARS-CoV-2 vaccines have reduced efficacy against the Omicron variant in immunocompetent individuals. Kidney transplant recipients (KTRs) have diminished antiviral responses to wild-type SARS-CoV-2 after vaccination, and data on antiviral responses to SARS-CoV-2 variants, including the Omicron variant, are limited.

Methods: We conducted a prospective, multi-center cohort study of 51 adult KTRs who received three doses of BNT162b2 or mRNA-1273. Blood and urine samples were collected before and four weeks after the third vaccine dose. The primary outcome was anti-viral antibody responses against wild-type and variants of SARS-CoV-2. Secondary objectives included occurrence of breakthrough SARS-CoV-2 infection and non-invasive monitoring for rejection using serum creatinine, proteinuria, donor-derived cell-free DNA and donor-specific antibodies. Sera from pre-pandemic healthy controls and KTRs were used for comparison.

Results: 67% of KTRs developed anti-wild-type spike antibodies after the third vaccine dose, similar to the Alpha (51%) and Beta (53%) variants, but higher than the Gamma (39%) and Delta (25%) variants. No KTRs had neutralizing responses to the Omicron variant before the third vaccine dose. After the third dose, fewer KTRs had neutralizing responses to the Omicron variant (12%) compared to wild-type (61%) and Delta (59%) variants. Three patients (6%) developed breakthrough SARS-CoV-2 infection at a median of 89 days. No KTRs developed allograft injury, *de novo* donor-specific antibodies or allograft rejection.

Conclusion: In KTRs, a third dose of mRNA vaccines increases antibody responses against wild-type and variants of SARS-CoV-2, while neutralizing responses to the Omicron variant remain markedly reduced.

Main text:

INTRODUCTION

Coronavirus disease (COVID-19) caused by severe acute respiratory coronavirus 2 (SARS-CoV-2) has resulted in over 800,000 deaths in the United States¹ with the Delta (B.1.617.2) and more recently the Omicron (B.1.1.529) variants accounting for the majority of cases.² Kidney transplant recipients (KTRs) are at increased risk of mortality following SARS-CoV-2 infection,³ and develop blunted antiviral responses following SARS-CoV-2 vaccination compared to non-transplant patients.⁴⁻⁶ Furthermore, the Delta and Omicron variants have been shown to be less sensitive to neutralizing antibodies from sera of vaccinated immunocompetent individuals,^{7,8} and similar data from vaccinated KTRs are limited.⁹ Therefore, in an era of clinically prevalent SARS-CoV-2 variants, evaluating antiviral responses to both wild-type (WT) and variants of SARS-CoV-2 in KTRs following SARS-CoV-2 mRNA vaccination is crucial. The aim of this study was to evaluate antiviral humoral responses against SARS-CoV-2 variants, including the Delta and Omicron variants following the third dose of SARS-CoV-2 mRNA vaccination in KTRs.

MATERIALS AND METHODS

Study design and patient recruitment

This is a prospective multicenter observational cohort study of the antiviral immune responses against SARS-CoV-2 variants following the third dose of SARS-CoV-2 mRNA vaccination in adult KTRs. Inclusion criteria were KTRs aged ≥ 18 years who were >3 months post-transplantation with stable allograft function and no rejection in the preceding six months. Full exclusion criteria are listed in supplementary materials. Subjects were enrolled consecutively.

Enrolled KTRs had received two doses of mRNA-1273 or BNT162b2 SARS-CoV-2 mRNA vaccines and were planned to receive a third dose of the same vaccine as per national guidelines. Participants had a baseline visit prior to the third vaccine dose and a follow-up visit one month following the third vaccine dose, where blood and urine samples were collected. Samples from fifteen pre-pandemic kidney transplant control patients and five pre-pandemic healthy controls were used for comparison.

Study approval:

The study was approved by the institutional review board at Mass General Brigham (IRB 2021P000043). All subjects signed written informed consent forms prior to enrollment in the study. The study was conducted in accordance with the Declaration of Helsinki and the Declaration of Istanbul. Data are reported in compliance with the STROBE statement reporting guidelines.

Outcomes

The primary outcome was the development of antiviral humoral responses following the third vaccine dose as assessed by 1) measurement of antibodies directed against the spike protein and receptor-binding domain (RBD) of WT and Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529) variants of SARS-CoV-2 by a Luminex-based multiplex assay and by enzyme-linked immunosorbent assay (ELISA); and 2) Antibodies neutralization capacity against WT, Delta and Omicron variants of SARS-CoV-2 using a surrogate virus neutralization test.¹⁰ Secondary objectives included 1) the occurrence of any severe or grade 4 related adverse events; 2) development of breakthrough SARS-CoV-2 infection; and 3) monitoring for rejection using serum creatinine, urine protein-to-creatinine ratio, donor-derived cell-free DNA

and donor-specific antibodies (DSAs). Details of sample processing and assays are described in supplementary materials and methods.

Statistics

Continuous variables are presented as means (\pm standard deviation) or as medians (with interquartile ranges or full ranges) depending on normality of distribution. Categorical variables are presented as frequencies and percentages. Differences between paired samples were assessed using a paired t-test, a Wilcoxon matched-pairs signed rank test, a repeated measures ANOVA or Friedman test as appropriate. For comparisons between continuous variables between three or more groups, if testing reached statistical significance, then pairwise testing was performed to determine significant differences between groups, using Dunn's correction to adjust for multiple comparisons. For categorical variables, the differences in proportions were calculated using a Pearson's Chi squared test or Fisher's exact test as appropriate. All tests used were two-sided and a two-sided α level of 0.05 was considered to be statistically significant. SPSS v24 (Chicago, IL) and GraphPad Prism v9.1.2 (San Diego, CA) were used for statistical analysis and creation of figures.

RESULTS

Patient characteristics

Fifty-one vaccinated KTRs were enrolled in the study. Baseline characteristics are shown in Table 1. Median age was 63 years, 43% were female and forty-eight (94%) patients received the BNT162b2 vaccine. The median time between the second and third vaccine doses was 187 days (IQR 181-193). Baseline samples were collected at a median of 5 days (IQR 0-18) prior to the

third vaccine dose and post-vaccination samples were obtained at a median of 29 days (IQR 26-33) post-vaccination.

Anti-spike antibody measurement

To evaluate antibody-mediated antiviral responses, we measured antibodies directed against the nucleocapsid (NC), spike trimer, S1 and RBD regions of the WT SARS-CoV-2 prior to and following the third vaccine dose in KTRs using a Luminex-based multiplex assay. After the third vaccine dose, there was no significant change in the MFI ratios of anti-NC antibodies ($p=0.278$) but there was a significant increase in the MFI ratios for antibodies directed against the spike trimer, S1 and RBD regions ($p<0.001$ for all, Fig. 1A). Using the recommended assay positivity threshold, all KTRs had a negative anti-NC antibody result before and after the third vaccine dose. The percentage of KTRs with anti-WT spike antibodies increased from 29% to 67% ($p<0.001$), anti-WT S1 antibodies increased from 10% to 47% ($p<0.001$) and anti-WT RBD antibodies increased from 12% to 45% ($p<0.001$) after the third vaccine dose. In comparison, all pre-pandemic healthy controls (HCs) and pre-pandemic kidney transplant patient controls (KCs) had negative results for antibodies against all four WT SARS-CoV-2 antigens (Fig. 1B). After the third vaccine dose, there was a significant increase in the MFI ratios of anti-spike antibodies directed against the Alpha, Beta, Gamma and Delta variants ($p<0.001$ for all, Fig. 1C), while all pre-pandemic HCs and KCs had undetectable antibodies against those variants (Fig. 1D). When evaluating differences in anti-spike antibody responses to SARS-CoV-2 variants, we found that prior to the third vaccine dose a higher percentage of KTRs (29%) had anti-spike antibodies against the WT virus compared to the Alpha (12%, $p=0.028$), Gamma (6%, $p=0.002$) and Delta (2%, $p<0.001$) variants but not the Beta variant (22%, $p=0.364$, Fig. 1E). After the third vaccine dose,

a higher percentage of KTRs (67%) had anti-spike antibodies against the WT virus compared to the Gamma (39%, $p=0.006$) and Delta (25%, $p<0.001$) variants but not the Alpha (51%, $p=0.108$) or Beta variants (53%, $p=0.158$, Fig. 1F).

Anti-RBD antibody measurement against Omicron variant and its neutralization capacity

Since the multiplex assay lacked assessment of antibodies directed against the new Omicron variant, we evaluated anti-RBD antibodies against the WT, Delta and Omicron variants using ELISA. After the third vaccine dose, there was a significant increase in anti-RBD antibody levels for the WT ($p<0.001$), Delta ($p<0.001$) and Omicron ($p<0.001$, Fig. 2A) variants. In comparison, pre-pandemic HCs and KCs had no detectable antibodies against the RBD proteins of the WT, Delta and Omicron variants (Fig. 2B). After the third vaccine dose in KTRs, anti-RBD antibody levels were higher for the WT compared to the Omicron variant ($p<0.001$) and similar between WT and the Delta variant ($p=0.142$). There was a trend towards lower anti-RBD antibody levels for the Omicron compared to the Delta variant, but this did not reach statistical significance ($p=0.110$).

We then evaluated neutralizing antibody responses using a surrogate virus neutralization test (SVNT).¹⁰ We found a significant increase in the percentage of neutralization against the WT ($p<0.001$), Delta ($p<0.001$) and Omicron variants ($p<0.001$, Fig. 2C) after the third vaccine dose. However, the percentage of neutralization was significantly lower for the Omicron variant compared to the WT and Delta variants ($p<0.001$). In comparison, there was no significant neutralizing response against the WT, Delta and Omicron variants in pre-pandemic HCs and KCs (Fig. 2D).

In addition, we found that the percentage of KTRs who had a neutralizing response increased from 29% to 61% for WT virus ($p=0.002$), from 24% to 59% for the Delta variant ($p<0.001$), and from 0% to 12% for the Omicron variant following the third vaccine dose ($p=0.012$, Fig. 2E). Prior to the third vaccine dose, fewer KTRs had a neutralizing response against the Omicron variant, compared to the WT ($p<0.001$) and Delta ($p<0.001$) variants, but there was no difference between the proportion of KTRs with neutralizing responses to the WT vs Delta variants ($p=0.501$). Similarly, after the third vaccine dose, fewer KTRs had a neutralizing response against the Omicron variant, compared to the WT ($p<0.001$) and Delta ($p<0.001$) variants, but there was no difference between the proportion of KTRs with neutralizing responses to the WT vs Delta variants ($p=0.840$). Moreover, the KTRs with neutralizing responses to the Delta variant but without anti-Delta spike antibodies by the multiplex assay had anti-WT spike antibodies.

Breakthrough infection after vaccination

At a median follow-up of 89 days (IQR 78-100) after the third vaccine dose, three patients (6%) developed symptomatic SARS-CoV-2 infection (Table 2). None had neutralizing responses to the Omicron variant and two did not have neutralizing responses to the WT and Delta variant. All had mild symptoms and were treated with monoclonal antibodies in the outpatient setting. All recovered without requiring hospital admission and none received dexamethasone or remdesivir.

Non-invasive rejection monitoring, allograft rejection and adverse events

No patients experienced severe adverse events post-vaccination. At a median of 29 days (IQR 26-32) after the third vaccine dose, no KTRs developed *de novo* DSAs and there was no significant

change in serum creatinine ($p=0.212$), urine protein-to-creatinine ratio ($p=0.257$), or donor-derived cell-free DNA levels ($p=0.434$, Table S1) compared to pre-vaccination. At a median follow-up of 89 days (IQR 78-100) after the third vaccine dose, no patients developed allograft rejection.

DISCUSSION

This study is one of the first to characterize antiviral humoral responses against SARS-CoV-2 variants, including the Omicron variant, after a third dose of SARS-CoV-2 mRNA vaccines in KTRs. Using a Luminex-based multiplex assay, we found that two thirds of KTRs had anti-WT spike antibodies after the third vaccine dose, similar to previous reports.¹¹⁻¹⁶ Despite an increase in the proportion of KTRs with anti-spike antibodies against WT SARS-CoV-2 and variants after the third vaccine dose, fewer KTRs had anti-spike antibodies against the Gamma and Delta variants compared to the WT, Alpha and Beta variants. Using an ELISA we developed in our laboratory, we found an increase in anti-RBD antibody levels against the WT, Delta and Omicron variants after the third vaccine dose, although anti-RBD antibody levels were significantly lower for the Omicron variant compared to WT virus. To assess neutralization capacity of antibody responses, we used a SVNT, which has been shown to be highly correlated with live virus neutralization assays.¹⁰ We found an increase in the percentage of neutralization against the WT, Delta and Omicron variants after the third vaccine dose as has been reported in immunocompetent individuals.^{17,18} About half of KTRs had neutralizing responses to the WT and Delta variants after third vaccine dose, consistent with what has been reported previously in KTRs.¹⁹ The presence of Delta variant neutralization in KTRs with anti-WT but not anti-Delta spike antibodies suggests cross-reactivity of anti-WT spike antibodies with the Delta variant. Concerningly, no KTRs had neutralizing responses to the Omicron variant prior to the third vaccine dose and only 12% had neutralizing responses to the

Omicron variant after the third vaccine dose. The Omicron variant's ability to escape neutralization compared to WT SARS-CoV-2 in our study is consistent with data from vaccinated immunocompetent individuals^{8,17,20,21} and is likely due to its highly mutated RBD region, which has 15 mutations compared to WT RBD.²²⁻²⁴ It is worth noting that a limitation of the SVNT is that it is not able to measure neutralizing antibodies directed against non-RBD regions of the spike protein as it only measures RBD-ACE2 interactions.

We were thus able to provide a detailed characterization of antibody responses to SARS-CoV-2 variants in KTRs, including the Omicron variant, and to evaluate the alloimmune safety of a third vaccine dose and found no evidence of allograft injury, *de novo* DSA development and no episodes of allograft rejection. This is consistent with what has been reported after two²⁵⁻²⁷ and three vaccine doses^{11,12,14} in solid organ transplant recipients. Our study has limitations, including its small sample size, observational design, lack of a control group of KTRs who did not receive a third vaccine dose, and lack of assessment of the cellular response to vaccination. Further studies evaluating the cellular response to the Omicron variant and the implications of the reduced neutralization ability with regards to risk and severity of infections in KTRs are needed.

In summary, we found that a third dose of SARS-CoV-2 mRNA vaccination in KTRs was associated with an increased antiviral antibody response against WT and variants of SARS-CoV-2, and while the neutralizing responses to the Omicron variant increased in some, overall they remained markedly diminished. Strategies designed to improve antiviral immune responses to the Omicron and future variants, such as with additional homologous²⁸ or heterologous²⁹ vaccine doses or use of higher vaccine doses, are also needed in this vulnerable high-risk group, in particular with the surge of Omicron as the predominant variant worldwide.

Author contributions:

Conceptualization: AAJ, RBG, TJB, ZS, JRA, LVR

Data curation: AAJ, LM, OE, ZS, RE

Formal analysis: AAJ, RBG, TJB, ITL, BB, VP, LVR

Funding acquisition: AAJ, JRA, LVR

Investigation: AAJ, RBG, TJB, ZS, RE, CD, ITL, BB, CK, LVR

Methodology: AAJ, RBG, TJB, ITL, OE, BB, VP, CK, JRA, LVR

Project administration: AAJ, ZS, RE, CD, LM, ITL, OE, VP, JRA, LVR

Validation: AAJ, ITL

Visualization: AAJ, RBG, TJB

Supervision: AAJ, ITL, BB, LVR

Writing-original draft: AAJ

Writing-review & editing: AAJ, RBG, TJB, ITL, CK, JRA, LVR

Acknowledgments:

We would like to thank the staff of the transplant clinic for their assistance in conducting this study.

Disclosures:

The authors have declared that no conflict of interest exists.

Funding:

The study was funded by CareDx, Inc. (Brisbane, CA) grant number 2021A008053 to LVR and JRA. The study was also supported in part by the Harold and Ellen Danser Endowed/Distinguished Chair in Transplantation at Massachusetts General Hospital (Boston, MA, USA). This was an investigator-initiated research project where the design and conduct of the study was determined by the investigator without influence from the funders.

Data availability statement:

Data to support the findings in the study are available from the corresponding author upon reasonable request.

Supplemental material table of contents:

Content	Page number in supplementary materials
Supplementary tables	2
Supplementary materials and methods	3-6
References	7

REFERENCES

1. CDC: COVID-19 Mortality Overview. [Internet]. 2021 Available from: <https://www.cdc.gov/nchs/covid19/mortality-overview.htm> [cited 2021 Nov 14]
2. CDC: Variant Proportions [Internet]. 2021 Available from: <https://covid.cdc.gov/covid-data-tracker/#variant-proportions> [cited 2021 Aug 12]
3. Caillard S, Chavarot N, Francois H, Matignon M, Greze C, Kamar N, Gatault P, Thauinat O, Legris T, Frimat L, Westeel PF, Goutaudier V, Jdidou M, Snanoudj R, Colosio C, Sicard A, Bertrand D, Mousson C, Bamoulid J, Masset C, Thierry A, Couzi L, Chemouny JM, Duveau A, Moal V, Blancho G, Grimbert P, Durrbach A, Moulin B, Anglicheau D, Ruch Y, Kaeuffer C, Benotmane I, Solis M, LeMeur Y, Hazzan M, Danion F, French SOT COVID Registry: Is COVID-19 infection more severe in kidney transplant recipients? *Am. J. Transplant* [Internet] 21: 1295–1303, 2021 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33259686>
4. Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, Garonzik-Wang JM: Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. *JAMA* [Internet] 325: 2204–2206, 2021 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33950155>
5. Benotmane I, Gautier-Vargas G, Cognard N, Olagne J, Heibel F, Braun-Parvez L, Martzloff J, Perrin P, Moulin B, Fafi-Kremer S, Caillard S: Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine. *Kidney Int.* [Internet] 2021 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33887315>

6. Rincon-Arevalo H, Choi M, Stefanski A, Halleck F, Weber U, Szelinski F, Jahrsdörfer B, Schrezenmeier H, Ludwig C, Sattler A, Kotsch K, Potekhin A, Chen Y, Burmester GR, Eckardt K, Guerra GM, Durek P, Heinrich F, Ferreira-Gomes M, Radbruch A, Budde K, Lino AC, Mashreghi M-F, Schrezenmeier E, Dörner T: Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. *Sci. Immunol.* [Internet] 6: 1–15, 2021 Available from: 34131023
7. Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira IATM, Datir R, Collier DA, Albecka A, Singh S, Pandey R, Brown J, Zhou J, Goonawardane N, Mishra S, Whittaker C, Mellan T, Marwal R, Datta M, Sengupta S, Ponnusamy K, Radhakrishnan VS, Abdullahi A, Charles O, Chattopadhyay P, Devi P, Caputo D, Peacock T, Wattal C, Goel N, Satwik A, Vaishya R, Agarwal M, Indian SARS-CoV-2 Genomics Consortium (INSACOG), Genotype to Phenotype Japan (G2P-Japan) Consortium, CITIID-NIHR BioResource COVID-19 Collaboration, Mavousian A, Lee JH, Bassi J, Silacci-Fegni C, Saliba C, Pinto D, Irie T, Yoshida I, Hamilton WL, Sato K, Bhatt S, Flaxman S, James LC, Corti D, Piccoli L, Barclay WS, Rakshit P, Agrawal A, Gupta RK: SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. *Nature* [Internet] 2021 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/34488225>
8. Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, Liu X, Lambe T, Crook D, Stuart DI, Mongkolsapaya J, Nguyen-Van-Tam JS, Snape MD, Screaton GR, Com-COV2 study group: Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. *Lancet (London, England)* [Internet] 2021 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/34942101>
9. Karaba AH, Zhu X, Liang T, Wang KH, Rittenhouse AG, Akinde O, Eby Y, Ruff JE,

- Blankson JN, Abedon AT, Alejo JL, Cox AL, Bailey JR, Thompson EA, Klein SL, Warren DS, Garonzik-Wang JM, Boyarsky BJ, Sitaras I, Pekosz A, Segev DL, Tobian AAR, Werbel WA: A Third Dose of SARS-CoV-2 Vaccine Increases Neutralizing Antibodies Against Variants of Concern in Solid Organ Transplant Recipients. *Am. J. Transplant* [Internet] 2021 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/34951746>
10. Tan CW, Chia WN, Qin X, Liu P, Chen MI-C, Tiu C, Hu Z, Chen VC-W, Young BE, Sia WR, Tan Y-J, Foo R, Yi Y, Lye DC, Anderson DE, Wang L-F: A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. *Nat. Biotechnol.* [Internet] 38: 1073–1078, 2020 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/32704169>
 11. Hall VG, Ferreira VH, Ku T, Ierullo M, Majchrzak-Kita B, Chaparro C, Selzner N, Schiff J, McDonald M, Tomlinson G, Kulasingam V, Kumar D, Humar A: Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. *N. Engl. J. Med.* [Internet] 2021 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/34379917>
 12. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A: Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. *N. Engl. J. Med.* [Internet] 2021 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/34161700>
 13. Benotmane I, Gautier G, Perrin P, Olagne J, Cognard N, Fafi-Kremer S, Caillard S: Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses. *JAMA* [Internet] 2021 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/34297036>
 14. Del Bello A, Abravanel F, Marion O, Couat C, Esposito L, Lavyssière L, Izopet J, Kamar

- N: Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. *Am. J. Transplant* [Internet] 2021 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/34331842>
15. Stumpf J, Tonnus W, Paliege A, Rettig R, Steglich A, Gemhardt F, Kessel F, Kroeger H, Arndt P, Sradnick J, Frank K, Tonn T, Hugo C: Cellular And Humoral Immune Responses after Three Doses of BNT162b2 mRNA SARS-Cov-2 Vaccine in Kidney Transplant. *Transplantation* [Internet] 2021 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/34342963>
 16. Masset C, Kerleau C, Garandeau C, Ville S, Cantarovich D, Hourmant M, Kervella D, Houzet A, Guillot-Gueguen C, Guihard I, Giral M, Dantal J, Blancho G: A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response. *Kidney Int.* [Internet] 100: 1132–1135, 2021 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/34474075>
 17. Nemet I, Kliker L, Lustig Y, Zuckerman N, Erster O, Cohen C, Kreiss Y, Alroy-Preis S, Regev-Yochay G, Mendelson E, Mandelboim M: Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection. *N. Engl. J. Med.* [Internet] 2021 Available from: <http://www.nejm.org/doi/10.1056/NEJMc2119358>
 18. Schmidt F, Muecksch F, Weisblum Y, Da Silva J, Bednarski E, Cho A, Wang Z, Gaebler C, Caskey M, Nussenzweig MC, Hatzioannou T, Bieniasz PD: Plasma Neutralization of the SARS-CoV-2 Omicron Variant. *N. Engl. J. Med.* [Internet] 2021 Available from: <http://www.nejm.org/doi/10.1056/NEJMc2119641>
 19. Kumar D, Ferreira VH, Hall VG, Hu Q, Samson R, Ku T, Ierullo M, Majchrzak-Kita B, Tomlinson G, Gingras A-C, Humar A: Neutralization of SARS-CoV-2 Variants in

- Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine : Secondary Analysis of a Randomized Trial. *Ann. Intern. Med.* [Internet] 2021 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/34807716>
20. Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, San JE, Cromer D, Scheepers C, Amoako D, Karim F, Bernstein M, Lustig G, Archary D, Smith M, Ganga Y, Jule Z, Reedoy K, Hwa S-H, Giandhari J, Blackburn JM, Gosnell BI, Karim SSA, Hanekom W, Network for Genomic Surveillance in, COMMIT-KZN Team, von Gottberg A, Bhiman J, Lessells RJ, Moosa M-YS, Davenport MP, de Oliveira T, Moore PL, Sigal A: Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. *Nature* [Internet] 2021 Available from: <https://www.nature.com/articles/d41586-021-03824-5>
 21. Carreño JM, Alshammary H, Tcheou J, Singh G, Raskin A, Kawabata H, Sominsky L, Clark J, Adelsberg DC, Bielak D, Gonzalez-Reiche AS, Dambrauskas N, Vigdorovich V, PSP/PARIS Study Group, Srivastava K, Sather DN, Sordillo EM, Bajic G, van Bakel H, Simon V, Krammer F: Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. *Nature* [Internet] 2021 Available from: <https://www.nature.com/articles/d41586-021-03846-z>
 22. Majumdar S, Sarkar R: Mutational and phylogenetic analyses of the two lineages of the Omicron variant. *J. Med. Virol.* [Internet] 2021 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/34964502>
 23. Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An R, Wang J, Wang Y, Niu X, Yang S, Liang H, Sun H, Li T, Yu Y, Cui Q, Liu S, Yang X, Du S, Zhang Z, Hao X, Shao F, Jin R, Wang X, Xiao J, Wang Y, Xie XS: Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. *Nature* [Internet] 2021

Available from: <https://www.nature.com/articles/d41586-021-03796-6>

24. He X, Hong W, Pan X, Lu G, Wei X: SARS-CoV-2 Omicron variant: Characteristics and prevention. *MedComm* [Internet] 2021 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/34957469>
25. Ou MT, Boyarsky BJ, Motter JD, Greenberg RS, Teles AT, Ruddy JA, Krach MR, Jain VS, Werbel WA, Avery RK, Massie AB, Segev DL, Garonzik-Wang JM: Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients. *Transplantation* [Internet] 2021 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33859151>
26. Cucchiari D, Egri N, Bodro M, Herrera S, Del Risco-Zevallos J, Casals-Urquiza J, Cofan F, Moreno A, Rovira J, Banon-Maneus E, Ramirez-Bajo MJ, Ventura-Aguiar P, Pérez-Olmos A, Garcia-Pascual M, Pascal M, Vilella A, Trilla A, Ríos J, Palou E, Juan M, Bayés B, Diekmann F: Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. *Am. J. Transplant* [Internet] 21: 2727–2739, 2021 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/34036720>
27. Grupper A, Rabinowich L, Schwartz D, Schwartz IF, Ben-Yehoyada M, Shashar M, Katchman E, Halperin T, Turner D, Goykhman Y, Shibolet O, Levy S, Houry I, Baruch R, Katchman H: Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. *Am. J. Transplant* [Internet] 2021 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33866672>
28. Kamar N, Abravanel F, Marion O, Romieu-Mourez R, Couat C, Del Bello A, Izopet J: Assessment of 4 Doses of SARS-CoV-2 Messenger RNA-Based Vaccine in Recipients of a Solid Organ Transplant. *JAMA Netw. open* [Internet] 4: e2136030, 2021 Available from:

<http://www.ncbi.nlm.nih.gov/pubmed/34817587>

29. Alejo JL, Mitchell J, Chiang TP-Y, Abedon AT, Boyarsky BJ, Avery RK, Tobian AAR, Levan ML, Massie AB, Garonzik-Wang JM, Segev DL, Werbel WA: Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. *Transplantation* [Internet] 105: e280–e281, 2021 Available from:

<http://www.ncbi.nlm.nih.gov/pubmed/34428188>

TABLES:

Table 1. Baseline characteristics of kidney transplant recipients.

Baseline characteristic	n=51
Age at enrollment (years), median (IQR)	63 (54-69)
Months between transplantation and 1 st vaccine dose, median (range)	43 (4-443)
Female sex, n (%)	23 (43)
Previous kidney transplant, n (%)	
None	47 (92)
One	3 (6)
Two	1 (2)
Cause of ESKD, n (%)	
Glomerular disease	21 (41)
Polycystic kidney disease	9 (18)
Diabetic nephropathy	5 (10)
Other genetic kidney disease	5 (10)
Lithium toxicity	2 (4)
Other or unknown	9 (18)
Pre-transplant RRT, n (%)	
None	19 (37)
Hemodialysis	27 (53)
Peritoneal dialysis	5 (10)
Donor source, n (%)	
Living related	11 (22)
Living unrelated	22 (43)
Deceased	18 (35)
Cold ischemia time (hours), median (IQR)	1.3 (0.8-12.1)
KDPI (%), median (IQR)	57 (42-69)
HLA ABDR mismatches, median (IQR)	4 (3-5)
Class I PRA (%), median (range)	0 (0-69)
Class II PRA (%), median (range)	0 (0-97)

Pre-transplant DSA, n (%)	2 (4)
DSA at the time of vaccination, n (%)	6 (12)
Induction immunosuppression, n (%)	
Anti-thymocyte globulin	28 (55)
Basiliximab	16 (31)
Data not available	7 (14)
Maintenance immunosuppression, n (%)	
Calcineurin inhibitor	
Cyclosporine	1 (2)
Tacrolimus	26 (51)
Trough level in ng/mL, median (IQR)	5.7 (4.9-6.6)
mTOR inhibitor	
Everolimus	2 (4)
Sirolimus	2 (4)
Belatacept	22 (43)
Mycophenolate	35 (69)
Total daily dose in mg, median (IQR)	1,000 (875-1,000)
Azathioprine	5 (10)
Total daily dose in mg, median (range)	62.5 (50-100)
Prednisone	42 (82)
Total daily dose in mg, median (IQR)	5 (5-5)
CMV serostatus, n (%)	
D+/R+	4 (8)
D+/R-	7 (14)
D-/R+	5 (10)
D-/R-	24 (46)
Not available	11 (22)
EBV serostatus, n (%)	
D+/R+	31 (61)
D+/R-	4 (8)
D-/R+	3 (6)
D-/R-	1 (2)
Not available	12 (24)
Delayed graft function, n (%)	10 (20)
History of allograft rejection, n (%)	11 (22)

Months between most recent rejection and 1 st vaccine dose, median (IQR)	30 (9-51)
Serum creatinine (mg/dL), median (IQR)	1.25 (1.05-1.59)
Estimated GFR (ml/min/1.73 m ²), mean ± SD	56 ± 17
Urine protein to creatinine ratio (g/g), median (IQR)	0.12 (0.07-0.36)
Donor-derived cell free DNA (%), median (IQR)	0.15 (0.00-0.23)
Previous SARS-CoV-2 infection, n (%)	4 (8)
mRNA vaccine received, n (%)	
BNT162b2	48 (94)
mRNA-1273	3 (6)
Days between 1 st and 2 nd vaccine dose, median (IQR)	21 (21-21)
Days between 2 nd and 3 rd vaccine dose, median (IQR)	186 (181-193)
ALC at time of 3 rd vaccine dose, cells/mm ³ , median (IQR)	1,395 (930-1,983)
ACE inhibitor or ARB use, n (%)	11 (22)

ACE: Angiotensin converting enzyme. ALC: Absolute lymphocyte count. ARB: Angiotensin receptor blocker. CMV: Cytomegalovirus. EBV: Epstein-Barr virus. ESKD: end-stage kidney disease. GFR: glomerular filtration rate. HLA: human leukocyte antigen. KDPI: kidney donor profile index. mTOR: mammalian target of rapamycin. PRA: panel reactive antibodies. RRT: renal replacement therapy. SD: standard deviation.

Table 2. Breakthrough SARS-CoV-2 infection after third dose of vaccination.

Study ID	Days after 3 rd vaccine dose	Maintenance IS regimen	Neutralizing response			Treatment	Outcome
			Wild-type	Delta	Omicron		
M10	99	Tacrolimus, MPA and prednisone	-	-	-	Bamlanivimab- etesevimab	Recovered
M36	78	Belatacept (monotherapy)	-	-	-	Bamlanivimab- etesevimab	Recovered
M37	89	Belatacept and prednisone	+	+	-	Casirivimab- imdevimab	Recovered

IS: immunosuppression. MPA: mycophenolic acid.

FIGURE LEGENDS:




Figure 1. Increase in anti-spike antibody levels after the third dose of SARS-CoV-2 mRNA vaccine in kidney transplant recipients (KTRs). (A) Antibody MFI ratios to wild-type (WT) SARS-CoV-2 antigens before and after the third vaccine dose in KTRs (n=51) and (B) in pre-pandemic healthy controls (HCs, n=5) and pre-pandemic kidney transplant control patients (KCs,

n=15) measured by Luminex-based multiplex assay. **(C)** Antibody MFI ratios for anti-spike antibodies of WT and variants of SARS-CoV-2 before and after the third vaccine dose in KTRs and **(D)** pre-pandemic HCs and KCs. Horizontal lines indicate positivity threshold for assay. **(E)** Proportion of KTRs with anti-spike antibodies against WT and variants of SARS-CoV-2 before and **(F)** after the third vaccine dose. **(A, C)** Statistic by Wilcoxon matched-pairs signed rank test. **(E, F)** Statistic by Chi-square test. NC: Nucleocapsid. RBD: Receptor-binding domain.




Figure 2. Poor anti-receptor binding domain (RBD) antibody and neutralization responses to the Omicron variant before and after the third dose of SARS-CoV-2 mRNA vaccine in

kidney transplant recipients (KTRs). (A) Anti-RBD antibody OD450 values to wild-type (WT), Delta (B.1.617.2) and Omicron (B.1.1.529) variants of SARS-CoV-2 before and after the third vaccine dose in KTRs (n=51), and (B) in pre-pandemic healthy controls (HCs, n=5) and pre-pandemic kidney transplant control patients (KCs, n=15) measured by enzyme-linked immunosorbent assay. (C) Percentage of neutralization to WT, Delta and Omicron variants of SARS-CoV-2 before and after the third vaccine dose in KTRs (n=51) and (D) in pre-pandemic HCs (n=5) and KCs (n=15) measured by surrogate virus neutralization test. Horizontal lines indicate positivity threshold for assay. (E) Proportion of KTRs with a positive neutralization response before and after the third vaccine dose in KTRs. (A, C) Statistic by Friedman test with Dunn's correction for multiple comparisons. (E) Statistic by Chi-square test.